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The elongation factor Tu has been identified as one of the most immunoreactive proteins
that was recognized by human sera of GBS (group B streptococcus) positive patients.
In this paper, we present the polypeptide-specific epitopes of the bacterial protein
that are recognized by human antibodies: 28LTAAITTVLARRLP41 (peptide no. 3) and
294GQVLAKPGSINPHTKF309 (peptide no. 21). To determine the shortest amino acid
sequence recognized by antibodies, truncation peptide libraries were prepared using
the PEPSCAN method. The analysis of immunoreactivity of peptides with sera of
GBS positive and negative women revealed that the most immunoreactive sequence
was 306HTKF309. Moreover, we observed that this sequence also showed the highest
specificity which was based on ratio of reactivity with sera of GBS positive relative to
sera of GBS negative patients. Epitope was synthetized on Wang resin with the Fmoc
strategy. Our results open the possibility to use 306HTKF309 peptide in diagnostic assays
to determine Streptococcus agalactiae infection in humans.
Keywords: Streptococcus agalactiae, group B streptococcus, elongation factor Tu, epitope mapping, vaccination,
synthetic peptide, PEPSCAN, ELISA
INTRODUCTION
Streptococcus agalactiae (group B streptococcus, GBS) is a Gram-positive bacterium that can
colonize human gastrointestinal and genitourinary tracts without any symptoms of diseases.
Ten to thirty percent of pregnant women are estimated to be colonized with GBS (Johri et al.,
2013), which can be dangerous for newborn children. In south-eastern Poland, the colonization
with S. agalactiae among pregnant women amounts to 30%, and the increase in the number
of infections in term newborns reaches 0.15 per 1,000 live births, whereas in the preterm
newborn incidence of infection increase to 6 cases per 1,000 live births (Brzychczy-Włoch
et al., 2013a,b; Centers for Disease Control and Prevention [CDC], 2015). In the 1980s, to
decrease the risk of GBS transmission to newborns, administration of antibiotic during labor
of GBS positive women was recommended by the American College of Obstetricians and
Gynecologists. Schrag et al. (2002) guideline recommended the antenatal screening approach or
evaluation of risk factors at the time of delivery for the administration of antibiotic intrapartum
prophylaxis. Only after revision of many additional data, CDC opted for universal antenatal
screening as the only option for the prevention of neonatal GBS disease (Centers for Disease
Control and Prevention [CDC], 2010 guideline). The methodology of GBS detection is based on
screening by vaginal-rectal swabbing. To identify GBS isolates, screening with selective enrichment
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broth is used and the results are known in about 48 h (Centers for
Disease Control and Prevention [CDC], 2010). Other methods
for GBS identification are as follows: CAMP test (Ratner et al.,
1986), serologic test (Guerrero et al., 2004), test on chromogenic
agars (non-hemolytic GBS is not detected; Votava et al., 2001),
or DNA analysis (Ryan et al., 1999; Goodrich and Miller, 2007).
Rapid diagnostics for carriage/infection in pregnant women,
especially those giving birth prematurely, would guarantee
immediate implementation of antibiotic prophylaxis/therapy.
When considering intermittent colonization with GBS, antenatal
screening can give false negative results which lead to the
occurrence of Early Onset Desease (EOD) in 20–30% of cases in
newborns delivered by pregnant women who were diagnosed as
healthy (Berardi et al., 2013; Schrag and Verani, 2013). A rapid
immunosorbent assay which is very sensitive and specific and is
able to show specific protective antibodies against GBS antigens
could be used to verify the fact that the pregnant women indeed
had been exposed to GBS. The rapid immunosorbent assay could
also be used in situations when the pregnant women had not
been subjected to antenatal screening, e.g., in premature labor.
New DNA-based rapid tests are not available in many countries,
what is affected by high costs of analysis and requires expensive
apparatus. Moreover, most of accessible molecular methods are
standardized to vaginal colonization diagnosis, while there are no
procedures for molecular identification of GBS in rectum, what
can lead to false negative results.
In our previous studies, elongation Tu factor was shown as
a highly immunoreactive protein that can be used as marker
of GBS infection and/or colonization (Brzychczy-Włoch et al.,
2013c). In this study, we would like to determine the most specific
epitope of the protein and check it as a marker of GBS infection
in enzyme-linked immunosorbent assay (ELISA) with human
GBS positive as well as GBS negative sera. The epitopes were
selected using PEPSCAN methodology. This technique allows to
synthesize many peptides in one tray linked to plastic pins and
then examine them in ELISA.
MATERIALS AND METHODS
Study Population and Specimen
Collection
The study group (n = 20) comprised pregnant women with
confirmed colonization by S. agalactiae according to CDC
recommendation (Centers for Disease Control and Prevention
[CDC], 2010). The control group (n = 14) consisted of pregnant
women not colonized with S. agalactiae.
The inclusion criteria:
- Pregnant women in the third trimester between 18 and 40
years of age
- A written statement of consent to participate in the study
The exclusion criteria:
- Pregnant women below 18 and over 40 years of age
- Patients with immunodeficiency or autoimmune diseases
- Pregnant women with the so-called high-risk pregnancy or
with perinatal complications
- Preterm delivery
- No written consent to participate in the study or its
withdrawal
The screening for GBS carriage in pregnant women was
performed at 35–37 weeks gestation. The swabs were collected
from the lower vagina (vaginal introitus), followed by the rectum
(i.e., inserted swab through the anal sphincter). Swabs were taken
separately by two sterile cotton swabs during the standard pelvic
examination in the third trimester of pregnancy. The procedure
for culture and identification of GBS in the studied materials
were conducted in accordance with the CDC recommendations
(Centers for Disease Control and Prevention [CDC], 2010).
Samples of approximately 50 ml of umbilical cord blood were
collected after the safe completion of delivery of patients included
in our investigation (n= 34), both from study group (n= 20) and
control group (n = 14) and were used to obtain serum. Serum
samples were stored at−70◦C in order to conduct immunoassays
on protein antigens of GBS. In addition, serum samples from
venous blood collected in the third trimester of pregnancy from
pregnant women colonized with GBS (n = 10), serum samples
collected in the third trimester of pregnancy from pregnant
women without GBS colonization (n = 8) and serum from
neonates with GBS EOD sepsis (n = 2) collected in the course of
the project number NN401042337 and described in our previous
paper were used (Brzychczy-Włoch et al., 2013c). The study was
approved by the Jagiellonian University Bioethical Committee
decision no. KBET/153/B/2014.
Bacterial Strains
Streptococcus agalactiae isolates (n = 120) were drawn from the
study group of pregnant women (n = 20), as well as from the
urinary tract infections (UTI; n = 100). The aim of the inclusion
of bacterial strains isolated from various infections types was
identification of common immunoreactive proteins, which could
be universal infection marker. The GBS strains from UTI were
isolated from urine samples from patients with S. agalactiae
bacteriuria ≥1 × 105 cfu/ml and were collected in the years
2009–2013 as part of the current diagnostics of the Microbiology
Laboratory of the Chair of Microbiology Jagiellonian University
Medical College in Krakow. The identification of GBS based on
PCR with species-specific primers was applied (Ke et al., 2000).
The molecular characterization of the tested GBS strains was
carried out according to the method described in our previous
publication (Brzychczy-Włoch et al., 2013c).
Protein Isolation and Analysis
Proteins were isolated and analyzed by slight modification
of a previously described procedure (Brzychczy-Włoch et al.,
2013c). Briefly, bacteria were cultured on brain heart infusion
broth (Biocorp) at 37◦C for 24 h. After centrifugation, they
were suspended directly in the buffer for electrophoresis
according to Heilmann et al. (1996). This made it possible
to isolate moonlighting proteins and preserve their native
structure. Protein concentration was analyzed using the Lowry’s
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method (Lowry et al., 1951). The immunoreactive proteins
were identified by immunoblotting within a complex protein
mixture that has been fractionated using discontinuous gradient
polyacrylamide gel (5, 7.5, 10, and 12.5%). Individual reactive
spots were cut out from gels and submitted to tryptic digestion,
then analyzed by mass spectrometry (spectrometer LC-MS/MS
Orbitrap, Thermo). Proteins were identified by Mascot1 (Matrix
Science, London, United Kingdom) and statistical methods.
Bioinformatic Analysis of Streptococcus
agalactiae Elongation Factor Tu
Predictions of epitope regions were made based on sequence
analysis. We used Genesilico Metaserver2 for predictions of
secondary structure elements and loop regions, disordered
regions, and protein solvation. Additionally, we used web server
for epitope localization prediction: Antibody Epitope Prediction3
applied methods—Emini Surface Accessibility Prediction (Emini
et al., 1985), Kolaskar & Tongaonkar Antigenicity (Kolaskar
and Tongaonkar, 1990) and Bepipred Linear Epitope Prediction
(Larsen et al., 2006), as another cross method BCPREDS
was used from B-cell epitope prediction server4. For more
detailed predictions, we used homology models made based
on 3D structure of PDB: 2C78 [elongation factor Tu (EF-TU)
complexed with a GTP analog and the antibiotic pulvomycin].
Based on the 3D structure of the modeled protein, we
identified loop regions on the surface of protein with tendency
to be disordered and which could be a good epitope. The
results obtained were used to make consensus predictions.
Any sequences that were positively selected by more than two
prediction methods and that contained more than six amino
acids were selected as linear epitopes.
Synthesis of Peptides Tethered to
Polyethylene Pins
Peptides corresponding to predicted epitopes were synthesized
using NCP Block of 96 hydroxypropyl methacrylate pins
(MIMOTOPES, Clayton, VIC, Australia) by stepwise elongation
of the peptide chain from the C- to the N-terminus, according
to the procedure described by Geysen et al. (1987) with slight
modifications. Each pin was suspended in 100 µl of the
solution containing 60 mM Fmoc amino acid and equimolar
amounts of diisopropylcarbodiimide (DIC) and 1-hydroxy-7-
azabenzotriazole (HOAt). Each coupling cycle lasted 6 h. Finally,
peptides were deprotected, washed with methanol (MeOH), then
with 0.5% acetic acid in MeOH and again with MeOH and dried.
Peptides were stored at−20◦C before use.
The Enzyme-Linked Immunosorbent
Assay (ELISA) with Peptides on Pins
Pins were disrupted in the buffer composed of 1% SDS, 0.1%
2-mercaptoethanol, and 0.1 M Na3PO4, pH 7.2, heated to 60◦C
1http://www.matrixscience.com
2https://genesilico.pl/meta2
3http://tools.immuneepitope.org/
4http://ailab.ist.psu.edu/
and placed in a sonication bath for 10 min. Pins were rinsed
with water and placed in a 60◦C water-bath for 5 min and
then in hot MeOH for 2–3 min. Before ELISA pins were
equilibrated with TBST (PBS + 0.05% Tween) for 10 min. at
25◦C. Pins were transferred to flat-bottom 96-well MaxiSorp
plates (Nunc) filled with 200 µl of 1% bovine serum albumin
(BSA) in TBST for 1 h at room temperature. They were then
immersed in 100 µl of the human umbilical cord serum (1:1,000)
and incubated for 2 h at 25◦C. Following three washes, the
alkaline phosphatase-conjugated goat anti-human IgG (1:10,000;
ICN Biomedicals, Aurora, OH, United States) were applied and
the plates were incubated at 25◦C for 1 h. The level of bound
conjugate was indicative of peptide antigenic activity and was
measured through the alkaline phosphatase activity. After five
washing steps with TBST, 200 µl of the p-nitrophenyl phosphate
(pNPP; liquid substrate for ELISA, Sigma) was used. To stop
the enzymatic reaction, pins were removed from the plate and
released p-nitrophenol was measured at 405 nm on a BioTek
Instruments (Tecan). To re-use pins they were disrupted and
stored at−20◦C with silica gel.
Solid Phase Peptide Synthesis
Synthesis of the polypeptides was performed on Wang resin
with the Fmoc strategy. Hundred milligrams of the resin was
incubated in 2 ml of N-dimethylformamide (DMF) for 1 h. The
resin activation was performed using 2 ml of 20% (v/v) piperidine
(PIP) dissolved in DMF, then it was washed six times with DMF.
A 0.5 mmol (5 equiv) of each Fmoc amino acid was used in
the elongation reaction as well as 43.7µl of HOAt and 43.9 µl
of DIC reagents. The elongation time was varying from 6 to
36 h depending on the amino acid residue. Next, the solvent
was drained and the resin was washed with DMF (6 × 2 ml).
The Fmoc protecting group was removed with a solution of
PIP/DMF (2/8, 2 ml) for 30 min (deprotection). The solution
was drained and the resin was washed with DMF. After the last
deprotection step, the resin was washed with DMF (6 × 2 ml),
dichloromethane (2 × 2 ml), and MeOH (2 × 2 ml). After last
washing, the resin was dried under vacuum. The peptides were
cleaved from the resin with trifluoroacetic acid (TFA; 95%) and
precipitated with cold diethyl ether. Next they were centrifuged
(4,000× g, 10 min× 2), dissolved in water and lyophilized. They
were stored at−20◦C.
The Purification of the Peptide
Sample preparation was performed by dissolving in a mixture
of water, acetonitrile, and formic acid (94.9, 5, 0.1% v/v/v).
Immediately before HPLC analysis, samples were filtered through
a 0.22 µm filter. The apparatus used was Dionex Ultimate
3000 System (Dionex Corporation, United States) equipped with
LPG-3400SD pump, WPS-3000T(B) FC Analytical autosampler,
TCC-3000SD column compartment and a DAD-3000 diode
array detector variable. The chromatography column was a C18
column (Phenomenex, 250 mm × 4.6 mm, 5 µm, 110 Å). The
following chromatographic conditions were applied: the mobile
phase: solvent A—0.1% formic acid in water; solvent B—0.1%
formic acid in acetonitrile. The program was as follows: 0 min—
5% solvent B; 15 min—95% solvent B; 16 min—95% solvent B;
Frontiers in Microbiology | www.frontiersin.org 3 February 2018 | Volume 9 | Article 125
fmicb-09-00125 February 2, 2018 Time: 18:18 # 4
Pyclik et al. Immunoreactive Epitope of Streptococcus agalactiae EF-Tu Protein
16.3 min—5% solvent B; 27.5 min—5% solvent B. The inject
sample volume was 100 µl. The flow rate was 0.5 ml/min and the
eluent was monitored at 254 nm at room temperature.
Analysis of the Peptide after Purification
Process
Samples from the purification process were lyophilized and
then dissolved in the mixture of water, acetonitrile, and
formic acid (94.9, 5, 0.1% v/v/v). Immediately before HPLC,
samples were filtered through a 0.22 µm filter and analyzed
on apparatus Dionex 3000 RS-HPLC equipped with a DGP-
3600 pump, a WPS-3000 TLS TRS autosampler, a TCC-3000
RS column compartment and a DAD-3000 RS diode array
detector variable (Dionex Corporation, United States). The
chromatography column was a 50× 3.1 (i.d)-millimeter Thermo
Scientific Hypersil GOLD with 1.9-micron particles (Part no.
25002-052130). The following chromatographic conditions were
applied: the mobile phase: solvent A—0.1% formic acid in water;
solvent B—0.1% formic acid in acetonitrile. The program was as
flows: 0 min—5% solvent B; 1 min—5% solvent B; 21 min—95%
solvent B; 21.5 min—95% solvent B; 21.6 min—5% solvent B;
30 min—5% solvent B. The inject sample volume was 4 µl. The
flow rate was 0.4 ml/min and the eluent was monitored at 254 nm
at room temperature. The peptide was analyzed in MALDI-TOF-
MS using α-cyano-4-hydroxycinnamic acid as a matrix. Five
microliters of the peptide solution (1 mg/ml) was mixed with
5 µl of the matrix (1 mg/ml in 80% acetonitrile containing 1%
TFA).
ELISA with the Peptide Coated on Plate
A 96-well MaxiSorp plate (NUNC, United States) was coated with
10 µg/well of the peptide in coating buffer (10 mM NaHCO3
buffer, pH 9.6) and incubated at 4◦C overnight. The plate was
washed three times with phosphate buffered saline containing
0.05% Tween-20 (PBST) after each incubation. Peptide-coated
plate was blocked by incubation with 200 µl blocking buffer
(1% BSA in PBST) at 37◦C for 1 h, and incubated with 100 µl
of human sera (1:1,000 dilution) in blocking buffer at 37◦C
for 45 min. Following three washes, the alkaline phosphatase-
conjugated goat anti-human IgG (1:10,000; ICN Biomedicals,
Aurora, OH, United States) were applied and the plates were
incubated at 25◦C for 1 h. The level of bound conjugate was
indicative of peptide antigenic activity and was measured through
the alkaline phosphatase activity. After five washing steps with
TBST, 200 µl of the pNPP (liquid substrate for ELISA, Sigma)
was used. To stop the enzymatic reaction, 2 M NaOH was added
and measured at 405 nm on a BioTek Instruments (Tecan).
Statistical Analyses
Statistical analysis was performed by one-way analysis of variance
followed by Tukey’s multiple comparison test using Prism 5.04
software (GraphPad, San Diego, CA, United States). P-values of
<0.05 were considered significant. Data are expressed as means
standard errors of the means (SEM).
RESULTS
Our previous studies revealed the existence of at least four
immunoreactive proteins present in 60 studied strains of
S. agalactiae, among which EF-Tu (44 kDa) was identified
(Brzychczy-Włoch et al., 2013c). In the current studies, we
expanded the studied test pool of GBS isolates by new
genetically different clinical strains (n = 120) as well as the
serum samples originating from umbilical cord blood of GBS-
positive (GBS+, n= 20) and GBS-negative (GBS−, n = 14)
patients. Proteins from three GBS isolates were subjected for
bioinformatics analysis, namely: (1) isolate no. D129 (sample
from adult with UTI), III serotype and rib gene; (2) isolate
no. 1736/08 (sample from neonate with UTI), serotype V, alp2
gene, cMLSB phenotype, and ermB gene; (3) isolate no. 13793/08
(sample from neonate with UTI), serotype V, alp3 gene, cMLSB
phenotype, and ermB gene. Again, we identified that the EF-Tu
exhibited the highest immunoreactivity. To predict the epitope
regions the bioinformatics analysis based on amino acid sequence
was made. Moreover, based on the 3D structure of the modeled
protein, we identified loop regions on the surface of protein with
TABLE 1 | List of the predicted synthetic epitopes of S. agalactiae elongation factor Tu.
No. Predicted epitope No. Predicted epitope
1 KEKYDRSKPHVNIG (3–16) 15 MSTVDEYIPEPERDTDK (196–212)
2 IGHVMH (18–23) 16 KPLLLPVEDVFSI (212–224)
3 LTAAITTVLARRLP (28–41) 17 RGTVASGRIDRGTVRV (227–243)
4 TSVNQPKDYASIDA (42–55) 18 VNDEVEIVGIK (244–252)
5 APEERERGITINTA (56–69) 19 QKAVVTGVEMFRKQLDEGLAGD (256–277)
6 HVEYETEKRH (70–79) 20 GDNVGVLLRGVQRDEIE (276–292)
7 HYAHIDAPGHADY (79–91) 21 GQVLAKPGSINPHTKF (294–309)
8 VKNMITGAAQM (92–102) 22 GEVYILSKEEGGRHTP (311–326)
9 GAILVVASTDGPMPQTR (104–120) 23 PFFNNYRPQFY (326–335)
10 TREHILLSR (119–127) 24 DVTGSIELPAG (341–351)
11 RQVGVKHLIVFMNKVDLV (127–144) 25 TEMVMPGDNVTIEVE (352–366)
12 LLELVEMRDLLSEY (149–164) 26 TIEVELIHPIAVEQG (362–376)
13 KEKYDRSKPHVNIG (3–16) 27 MSTVDEYIPEPERDTDK (196–212)
14 IGHVMH (18–23) 28 KPLLLPVEDVFSI (212–224)
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FIGURE 1 | Recognition of the pin-tethered peptides representing predicted
epitopes of S. agalactiae by human umbilical cord sera (pooled sera of GBS+)
in ELISA. The empirical studies showed that two of the peptides were
immunodominant in reaction with GBS+ sera (peptide no. 3 and 21).
Experiments were performed in triplicate and results represent the mean of
the Absorbance index ± SEM.
FIGURE 2 | Reactivity of peptide no. 3 and its derivatives (A) as well as
peptide no. 21 and its derivatives (B) with human umbilical cord sera (pooled
sera of GBS+—in ELISA. The peptides (no 3 and no 21) were modified by
removing the residues flanking of the N and C ends. Three epitopes were
selected as the most immunoreactive: TVLARRLP—Ep1 (A);
KPGSINPHTKF—Ep2 and HTKF—Ep3 (B). Experiments were performed in
triplicates and results represent the mean of the Absorbance index ± SEM.
a tendency to be disordered and which could be a good epitope.
In general, we projected 28 potential epitopes (Table 1).
To identify which of the projected epitopes are recognized
by immunoglobulins, peptides (in the form of 6-mer to 20-
mer peptides) bearing the sequence of the predicted epitopes
were synthesized using pin technology and tested for their
immunoreactivity with pooled human sera GBS− and GBS+.
We used the pooled sera due to the limitation of reusability
of pins in ELISA test. The ELISA results showed that
two peptides: 28LTAAITTVLARRLP41 (peptide no. 3) and
294GQVLAKPGSINPHTKF309 (peptide no. 21) exhibited the
highest immunoreactivity (Figure 1). To identify the shortest
amino acid sequence necessary for recognition by the umbilical
cord sera antibodies, we prepared the truncation peptide libraries.
The libraries were constructed by systemically removing the
residues flanking of the N and C ends from the original peptides
(Figures 2A,B). The reactive sera showed the highest reactivity
with sequences 35TVLARRLP41 (a part of the peptide no. 3—
Ep1) and 299KPGSINPHTKF309 (a part of peptide no. 21—
Ep2) or only 306HTKF309 (a part of peptide no. 21—Ep3). To
identify specific amino acid residues responsible for peptide’s
activity the alanine/glycine scanning was performed. Each of the
eight residues in Ep1 were systematically replaced by glycine,
whereas each of the eleven or four residues in Ep2 or Ep3, were
systematically replaced by alanine. We have shown that in the
case of Ep1 the substitution of each amino acid by glycine caused
the immunoreactivity decrease. However, Thr, Ala, and two Arg
residues were the most crucial for the interaction with human
antibodies. The reduction of the immunoreactivity of the peptide
no. 21 derivatives was also observed. It was shown that the Lys
residue was the most important for antibody binding (Figure 3).
To analyze the peptide reactivity with human sera three
parameters were considered: the average absorbance at
l = 405 nm with GBS+, the average absorbance with GBS−
and their percentage ratio. Although Ep1 showed very high
immunoreactivity with GBS+ sera, the reactivity with GBS−
was also high. The average absorbance at l = 405 nm in
ELISA for GBS− sera was 1.45 and represented 64% of the
GBS+ absorbance (that indicated low specificity). To improve
the specificity of the epitope, the Thr residue was replaced
by Ser. The absorbance ratio of GBS+ and GBS− declined
(35%), however, the absorbance of the negative sera was still
high (0.71). The substitution of one Arg with Leu in this
peptide—TVLARLLP—and substitution of two Arg by Ala
residues—TVLAALP—declined these rates (absorbance for
negative GBS and absorbance ratio) to 0.206 with 31% ratio
and 0.16 with 28% ratio, respectively. Ep2 and Ep3 were
modified by replacing the Lys residues by Arg or Glu. None
of the modifications improved the parameters of the reactivity
(Figure 4). All modifications of three epitopes are summarized
in Table 2 which showed the absorbance for GBS+, GBS−,
and the absorbance ratio. Taking into account the limitations
of the PEPSCAN method (peptides were immobilized on pins),
we decided to synthesize the peptides in free form. We chose
peptide 306HTKF309 due to the highest reactivity of sera from
GBS positive patients. To check the immunoreactivity of the
non-immobilized epitopes we synthesized them on Wang resin
with the Fmoc strategy as described above. After chemical
synthesis Ep3 was purified by HPLC and analyzed in MALDI as
well as in ELISA with GBS+ and GBS− sera. The molecular mass
of Ep3 was 616.64 Da and was about 85.036 Da higher than the
calculated mass. The epitope showed the immunoreactivity with
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FIGURE 3 | Reactivity of Ep1 (A), Ep2 (B), and Ep3 (C) and their derivatives
with human umbilical cord sera (pooled GBS+ and pooled GBS– sera) in
ELISA. Ep1 and Ep2 were modified by each amino acid substitution by glycine
(A) or alanine (B,C). The substitution of each amino acid by glycine in Ep1 or
alanine in Ep3 caused the immunoreactivity decrease. In Ep, Thr, Ala, and two
Arg, residues were the most crucial for the interaction with human antibodies,
whereas in Ep2 and Ep3, the Lys residue was the most important for antibody
binding. Experiments were performed in triplicates and results represent the
mean of the absorbance index ± SEM. ∗∗∗∗p < 0.0001, ∗∗∗p < 0.001,
∗∗p < 0.01, ∗p < 0.05; ns, no significance.
GBS positive serum that in fact was not as high as for epitope
immobilized to pin. The average absorbance at l = 405 nm was
0.39, while the reactivity against GBS− serum was not observed
(Figure 5). The average absorbance for GBS− was 0.21 and was
FIGURE 4 | Reactivity of Ep1, Ep2, and Ep3 and their derivatives with human
umbilical cord sera (pooled GBS+ and pooled GBS– sera) in ELISA. Ep1 was
modified by substitution: Thr-Ser, Arg-Leu, ArgArg-AlaAla. Ep2 and Ep3 were
modified by Lys-Arg or by Lys-Glu substitution. The substitution of one Arg
with Leu or substitution of two Arg by Ala in Ep1 declined the absorbance for
negative GBS and absorbance ratio. None of the modifications improved the
parameters of the reactivity of the Ep2 and Ep3. Experiments were performed
in triplicates and results represent the mean of the absorbance index ± SEM.
∗∗∗p < 0.001.
identical as for the reagent sample. The percentage ratio of the
absorbance GBS+ and GBS− was 54%. The experiment proved
that the chosen epitope shows the specific immunoreactivity
being immobilized as well as in the free form.
DISCUSSION
Currently, no quick diagnostic tests are available on the global
market that would confirm the infection caused by S. agalactiae.
Traditionally used diagnostic methods are based on culturing,
the results of which are characterized by low sensitivity and
long waiting periods (up to several days). Rapid diagnosis
aimed at detecting carriers and infections caused by GBS
guarantees immediate implementation of the targeted prevention
or treatment. We identified specific epitopes of the bacterial
protein EF-Tu that are recognized by human antibodies. EF-Tu
is one of the most abundant and conserved bacterial proteins. It
plays a central role in the elongation phase of protein synthesis
and translation process in prokaryotic cells (Barbier et al., 2013).
EF-Tu is a component of the bacterial membrane cytoskeleton
involved in adhesion to the host cells in several pathogenic
bacteria (Mayer, 2006) and was found also on the surface
(Granato et al., 2004). EF-Tu is also known as a moonlighting
protein that exhibits multiple biological functions involved in
bacterial pathogenesis. It has been already shown that EE-Tu
is involved in adhesion, invasion, and modulation of the host
immune system (Kunert et al., 2007; Araujo et al., 2008; Mohan
et al., 2014). In our previous study, the EF-Tu was identified as
one of the most immunoreactive proteins that was recognized
by human sera of GBS positive patients (Brzychczy-Włoch et al.,
2013c). Other investigators have demonstrated that EF-Tu is
one of the virulence factors of other bacterial infections. For
example, Carrasco et al. (2015) demonstrated that EF-Tu is highly
immunogenic in mice infected with Borrelia burgdorferi and in
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TABLE 2 | Reactivity of modified epitopes with GBS+ and GBS− sera in ELISA.
A405 nm GBS+ A405 nm GBS− A405 nm
GBS+/A405 nm GBS−
SVLARRLP 1.424 0.7155 50%
TVLARLLP 0.653 0.206 31%
TVLALLLP 1.437 0.511 35%
TVLARELP 0.523 0.244 46%
TVLAEELP 0.3575 0.14 39%
TVLAAALP 0.5735 0.16 28%
RPGSINPHTKF 0.43 0.139 32%
KPGSINPHTRF 0.458 0.132 29%
RPGSINPHTRF 1.8315 1.4625 79%
KPGSINPHTEF 0.706 0.246 35%
EPGSINPHTEF 1.5655 0.954 61%
KPGSIDPHTKF 0.51 0.14 27%
EPGSIDPHTEF 0.409 0.168 41%
HTRF 0.832 0.245 29%
HTEF 0.385 0.1305 34%
EPGSINPHTKF 0.292 0.177 60%
HTKF 0.873 0.23 26%
KPGSINPHTKF 1.34 0.284 21%
TVLARRLP 2.3075 1.4795 64%
The absorbance (reactivity) value for unmodified peptides is marked.
Lyme disease patients. Moreover, Jiang et al. (2016) suggested
that EF-Tu may be a potential candidate for vaccine development
against Mycoplasma ovipneumoniae infection in sheep. Recently,
Widaja et al. (2017) indicated that EF-Tu moonlights on
the surface of bacteria are a target of proteolytic processing
events and suggested that studies are needed to determine how
processing generates biologically important effector molecules
and if protein processing is fundamental to the expansion of
protein function in bacteria belonging to different phylogenetic
clades.
Blast analysis indicates that the EF-Tu protein sequence
from S. agalactiae is conserved. However, studies on moonlight
proteins have shown that these proteins can change their spatial
FIGURE 5 | Reactivity of Ep3, with human umbilical cord sera (pooled GBS+
and pooled GBS– sera) in ELISA. The epitope showed the immunoreactivity
with GBS+ serum, while the reactivity with GBS– serum was not observed.
Experiments were performed in triplicates and results represent the mean of
the absorbance index ± SEM. ∗∗p < 0.01.
structure depending on the environment in which they are found.
They may also be present in protein complexes, which may cause
the exposure of other amino acid residues to the outer side of
the protein in the case of membrane proteins (Jeffery, 2015). It
was interesting to identify epitopes of this protein that evoke an
immune response in GBS patients and open the possibility to
use S. agalactiae EF-Tu as a potential antigen for serodiagnostic
marker during GBS infection.
In this paper, we performed prediction analysis of presumable
epitopes which are recognized by human antibodies with specific
manner. The prediction was based upon amino acid sequence,
additionally, we identified loop regions on the surface of the
protein with a tendency to be disordered and which could be
a good epitope candidate. This strategy allowed us to avoid
the time-consuming continuous epitope analysis using Geysen
procedure, which in case of EF-Tu (405 amino acid residues),
would entail the combination (including overlapping peptides)
of 8-mer peptides to result in about 400 combinations. Using
bioinformatics analysis strategy, the total amount of projected
epitopes were 28 (Table 1). The epitopes were synthesized on pins
using the Fmoc strategy.
The empirical studies showed that two of the peptides were
immunodominant in reaction with GBS+ sera (Figure 1).
Another criterion for peptide selection was the lowest reactivity
with GBS− sera, which is an evidence for the specificity of the
peptides. Further modification of the original peptides gave us
the shortest reactive epitopes with good specificity (Figure 2).
In our study, as a background, we took the mean absorbance
readings up to 30% of the mean absorbance obtained for positive
sera for the same epitope. The goal of the immunoreactive
peptide modification, namely cutting as well as amino acids
replacing, was to obtain the epitopes as short as possible, but
not shorter than four amino acids. The modification consisted in
exchanging those amino acid residues that were most important
for immunoreactivity (Figure 3). The important residues were
substituted by amino acids containing similar physical properties:
Thr was substituted by Ser, Arg by Leu, Lys by Arg. We also
checked the immunoreactivity of Ep3 after Lys substitution by
acidic amino acid—Glu (Table 2). None of the modifications
caused immunoreactivity improvement except substitutions in
Ep1, where one Arg was exchanged by Leu and two Arg by Ala
residues (Figure 4). The immunoreactivity improvement should
not surprise, because based on Kolaskar’s studies, Leu and Ala
residues in general are often present in epitopes unlike the Arg
residue.
Epitopes immobilized to pins can be reused only few times
hence we used the PEPSCAN methodology only to determine the
most specific epitopes against the pooled sera. The pooled sera
consisted of umbilical cord blood sera of 15 individual patients
that contained protected antibodies transferred from the mother’s
blood. To analyze 100 or more human sera, we had to synthesize
the epitope peptides and use them in the free form in ELISA.
We decided to synthesize the shortest one of the epitope Ep3
and checked its reactivity. Ep3 was synthesized on resin using
the standard methodology. After purification, we obtained 1 mg
of Ep3 fragment peptide. Its molecular mass was higher than
calculated (about 85.036 Da) which corresponds to molecular
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mass of PIP that was used during the synthesis procedure. We
suggest that in the wake of the Thr residue a β-elimination
reaction took place. The hydroxyl moiety was removed forming a
dehydroalanine intermediate which reacts with the deprotecting
base PIP, to form a 3-(1-piperidinyl)-alanine residue.
Ep3 was further analyzed in ELISA and its reactivity was
not as high as in ELISA experiment with the same epitope
immobilized to pin (Figure 5). The main reason of the difference
could be insufficient physical adsorption of the free peptide
to the plate. The short peptide could be washed out during
ELISA performance. However, the methodology of the epitopes
bounding to the plate (coating) should be improved. Linear
epitopes should have from 5 to 22 amino acid residues (Andersen
et al., 2006) or six to nine polar amino acids (Atassi, 1975),
however, our Ep3 epitope is a tetrapeptide but exhibited the
same reactivity as peptide no. 21. Moreover, we showed that
each additional amino acid reduced its immunoreactivity, the
specificity of this short sequence was 13 times higher than the
modified sequence. The results obtained in the ELISA experiment
give us a reason to expect that the two other epitopes would also
be immunoreactive in the free form like Ep3.
The results of our studies show that to identify the presence
of specific antibodies against S. agalactiae infection in humans
we can use short, synthetic, specific epitopes that belong
to elongation Tu factor. The protein is one of the most
immunoreactive proteins of the Streptococcus strains that induce
antibodies production in a natural way. The advantages of the
epitopes are their high specificity, high yield and fast production
process. Combination of two or three epitopes could further
improve the diagnostic test based on the ELISA procedure. The
epitopes could be also used as vaccine components, because, as we
showed, the protective antibodies are transferred transplacentally
from mother to child. However, we strongly emphasize that
further, advanced research should be carried out.
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